Last reviewed · How we verify
Intraanal NRL001 Gel 2 strengths — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intraanal NRL001 Gel 2 strengths (Intraanal NRL001 Gel 2 strengths) — Norgine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intraanal NRL001 Gel 2 strengths TARGET | Intraanal NRL001 Gel 2 strengths | Norgine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intraanal NRL001 Gel 2 strengths CI watch — RSS
- Intraanal NRL001 Gel 2 strengths CI watch — Atom
- Intraanal NRL001 Gel 2 strengths CI watch — JSON
- Intraanal NRL001 Gel 2 strengths alone — RSS
Cite this brief
Drug Landscape (2026). Intraanal NRL001 Gel 2 strengths — Competitive Intelligence Brief. https://druglandscape.com/ci/intraanal-nrl001-gel-2-strengths. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab